)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Sagimet Biosciences
Sagimet Biosciences (SGMT) investor relations material
Sagimet Biosciences Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary12 Nov, 2026
Executive summary
First patient dosed in the registrational U.S. AURORA Phase 3 trial of denifanstat for moderate to severe acne; topline data expected in H2 2027.
October financing lifted pro forma cash to $355.8M, expected to fund operations through mid-2029, including the AURORA readout and potential NDA submission.
Financial highlights
Q3 R&D expense rose 68% YoY to $16.3M from $9.7M, largely reflecting denifanstat acne Phase 3 activity and manufacturing.
Q3 G&A expense was $5.2M versus $4.6M; total operating expenses were $21.6M versus $14.3M.
Q3 net loss was $19.1M versus $12.9M; 9M net loss was $43.8M versus $41.5M.
9M operating cash use was $31.8M versus $33.8M; cash and cash equivalents were $111.0M at September 30.
Outlook and guidance
AURORA plans to enroll ~800 U.S. patients aged 12 and older, including ~450 adolescents; denifanstat 50 mg versus placebo will be assessed over 12 weeks.
TVB-3567 Phase 2 in moderate to severe acne is expected to start by year-end 2026; development of a topical FASN inhibitor will continue.
FDA consultation on a denifanstat-resmetirom MASH Phase 2 design is anticipated in Q1 2027; further MASH clinical development awaits non-dilutive financing.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Sagimet Biosciences
- Denifanstat’s U.S. phase III is underway, with primary results targeted by end-2027.SGMT
3rd Annual Guggenheim Healthcare Innovation Conference - 52-week denifanstat data support a planned U.S. Phase 3 acne trial.SGMTKOL event
- Denifanstat's phase III acne program advances with FDA backing, strong data, and broad commercial ambitions.SGMT12th Annual Cantor Fitzgerald Global Healthcare Conference
- Denifanstat targets moderate to severe acne with strong efficacy, safety, and broad market potential.SGMTCanaccord Genuity's 46th Annual Growth Conference
- Q2 net loss was $14.0M, cash at $257.6M, and Phase 3 acne trial set for late 2026.SGMTQ2 2026
- Phase III acne trial for a novel oral therapy to launch in U.S., with topical programs in development.SGMTH.C. Wainwright 4th Annual BioConnect Investor Conference
- $175M financing extends cash runway through 2028 as US Phase 3 acne trial is planned.SGMTQ1 2026
- Advancing denifanstat combinations for MASH and novel oral therapy for acne, with strong financial runway.SGMTTD Cowen 46th Annual Health Care Conference
- Denifanstat showed robust Phase 3 results; TVB-3567 is advancing with strong IP and US expansion.SGMTKOL Event
Next Sagimet Biosciences earnings date
Q4 202611 Mar, 2027
Sagimet Biosciences
Next Sagimet Biosciences earnings date
Q4 202611 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Sagimet Biosciences Inc., previously known as 3-V Biosciences, Inc., is a clinical-stage biopharmaceutical company. It focuses on developing innovative therapeutics called fatty acid synthase (FASN) inhibitors. These inhibitors target diseases caused by the overproduction of the fatty acid, palmitate, including non-alcoholic steatohepatitis (NASH), acne, and various forms of cancer. Sagimet Biosciences' expertise in fatty acid synthase allows it to pioneer treatments for these diseases by targeting dysfunctional metabolic pathways. Its lead product candidate, denifanstat, is an oral, once-daily selective FASN inhibitor, currently being evaluated in clinical trials for patients with NASH. The company was incorporated in 2006 and is headquartered in San Mateo, California, USA. Its shares are listed on the Nasdaq.